# Analytical Evidence Report

HPLC-DAD results for the submitted BPC-157 and TB-500 blend sample

REPORT NUMBER
**WB-BPCTB-20-092126**

GENERATED
**October 26, 2026**

## BPC-157 and TB-500 blend

Sample 6026_0102 | Client report WB-BPCTB-20-092126

**Results and chromatograms**

**Client: Wes Blakely**

**Laboratory Analysis: Testides analytical laboratory**

Laboratory identity and applicable credentials are maintained by Testides and are available to regulatory authorities where required by law.

| VIAL PHOTOGRAPH | SAMPLE INFORMATION | | ANALYSIS | | RUN DETAILS | |
|---|---|---|---|---|---|---|
|  | Peptide: | **BPC-157 and TB-500 blend** | Method: | **HPLC-DAD** | Run date: | **Sep 26, 2026** |
| | Sample ID: | **6026_0102** | Components: | **2 listed, 2 found** | First acquired: | **03:06:03 UTC** |
| | Client ID: | **WB-BPCTB-20-092126** | Injections: | **1 of the vial** | Last acquired: | **03:06:03 UTC** |
| | Label claim: | **20 mg** | Identity: | **1 of 2 supported** | Run time: | **8.0 min** |


## RESULTS AT A GLANCE

| PROJECTED AMOUNT | LOWEST COMPONENT PURITY | CONTENT VS. LABEL | COMPONENTS FOUND |
|---|---|---|---|
| **23.35 mg** | **99.96%** | **116.8%** | **2 of 2** |
| SUM OF COMPONENTS FOUND | 214 NM, EACH AT ITS OWN PEAK | 23.35 MG OF 20 MG CLAIMED | EACH READ IN ITS OWN INJECTION |

| TB-500 | BPC-157 |
|---|---|
| **13.25 mg** | **10.10 mg** |
| 132.5% OF 10 MG SHARE | 101.0% OF 10 MG SHARE |

## CHROMATOGRAM

**Every injection of the vial - 214 nm detector response, each component labelled at its own peak**




## COMPONENT PEAKS (214 NM)

| Component | Injection (method) | RT (min) | Area | Purity | Amount | Label share | Content | UV match | Identity |
|---|---|---|---|---|---|---|---|---|---|
| TB-500 | BPC-157, TB-500 & KPV | 0.918 | 15.656 | 99.96% | 13.25 mg | 10 mg | 132.5% | 1.00000 | Supported |
| BPC-157 | BPC-157, TB-500 & KPV | 2.031 | 36.982 | 99.96% | 10.10 mg | 10 mg | 101.0% | 1.00000 | Supported |

Each component is read in the vial's injection on the method that runs it, at its own retention time, against that method's same-run standards, with the preparation the laboratory lists for it. The projected amount is the sum of the components found. Purity is each component's share of the integrated area in its own injection; peaks of the blend's other components are not counted as impurities.

The chromatogram shows each of the vial's 1 injection(s) on its own method's time axis (1,200 native readings, no smoothing), drawn on a straight baseline; each injection is shown less its method's bracketing blank injections, as it was integrated.

TB-500: reference potency missing; no impurity detected; purity from a single injection; reporting limit above target; the standards' own purity disagrees with the sample's; content outside the plausible range.

BPC-157: no impurity detected; purity from a single injection; reporting limit above target.

## BPC-157 and TB-500 blend


Sample 6026_0102 | Client report WB-BPCTB-20-092126

**Reference comparison and calculation**

**Client: Wes Blakely**

## CONCENTRATION CALIBRATION - ONE CURVE PER COMPONENT

### TB-500 - same-run curve, 214 nm




Area = 0.107469C +1.41857 | R2 0.99951

**15.656 = 132.48 ug/mL x 2 x 50 / 1000 = 13.25 mg**

### BPC-157 - curve through the origin, 214 nm


Area = 0.366061 C, least squares over 2 levels through the origin (WB-BPC-10-092126 (LR-20260921-01): 36.776 at 100 ug/mL; WB-BPC-5-092126 (LR-20260921-01): 36.436 at 100 ug/mL). 36.982 = 101.03 ug/mL x 2 x 50 / 1000 = 10.10 mg.

## FROM PEAK AREA TO AMOUNT


| Component | Channel | Curve | RT (min) | Std RT | UV match | ug/mL | Prep. | Amount | Content |
|---|---|---|---|---|---|---|---|---|---|
| TB-500 | 214 nm | Same-run standards | 0.918 | 0.918 | 1.00000 | 132.48 | 2 x 50 | 13.25 mg | 132.5% |
| BPC-157 | 214 nm | Curve through origin | 2.031 | 2.032 | 1.00000 | 101.03 | 2 x 50 | 10.10 mg | 101.0% |

## COMPONENT PEAKS COMPARED WITH THE SAME-RUN REFERENCE

### TB-500




### BPC-157




Each curve is the unweighted least-squares line through its method's same-run standards; the sample's area on the curve's channel gives its concentration, and the preparation the laboratory lists for the component scales it to the vial. Peaks are native readings with the exact integration baselines; the dashed line marks the standards' retention-time centre.

** Reference alignment: retention time within the same-run standards' range or within ±10% of their mean, and a UV match (220-300 nm cosine) at or above the standards' lowest, 0.999, or 0.98 where retention conforms.

## BPC-157 and TB-500 blend

Sample 6026_0102 | Client report WB-BPCTB-20-092126

**Definitions, calculation detail, and scope**

**Client: Wes Blakely**

## HOW TO READ THIS REPORT

Start with the results on page 1. Page 2 shows each component's curve and its comparison with its standard.

**01** **One chromatogram**

Every injection of the vial, each component labelled at its own peak.

**02** **Component table**

Each component's retention time, area, purity, amount and identity.

**03** **Curve and standard**

Each component's calibration, and its peak against its same-run standard.

## HOW EACH COMPONENT'S PURITY WAS MEASURED

### 214 nm area percent, in each component's own injection

Each injection is corrected against the blanks bracketing it, every peak is integrated to a valley-to-valley baseline, and a component's purity is its peak's share of the counted area. Peaks where the blend's other components elute are not counted against it. The largest peaks behind each result are listed.

| Component | RT (min) | Area | Area % | Classification | UV vs main | Counted |
|---|---|---|---|---|---|---|
| TB-500 | 0.918 | 14.1769 | 100.000 | Main peak | - | Counted |
| | 2.031 | 37.9236 | - | blend component | 0.997 | Excluded |
| BPC-157 | 2.031 | 37.9499 | 100.000 | Main peak | - | Counted |
| | 0.918 | 14.4807 | - | blend component | 0.997 | Excluded |

## WHAT THIS REPORT CAN AND CANNOT TELL YOU

### The report explains the measurement; it does not decide how a material should be used

**Observed evidence**

The vial's injections, each component's same-run standards and curve, and classified peaks.

**Calculated results**

Each component's amount, content against its share of the label, and 214 nm purity.

**Method context**

Retention time (standards' range or ±10%) and UV match (standards' lowest, 0.999, or 0.98 with retention).

**Safety and regulatory status**

No conclusion on safety, efficacy, fitness for use, or regulatory status.

This analytical record does not authorize or endorse manufacture, sale, marketing, distribution, or use of the material.